Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 3/20 | 0.49 |
| ▸ | ARG1 | P05089 | 1/20 | 0.45 |
| ▸ | ARG2 | P78540 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | BHMT | Q93088 | 6/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5061193 | 1.00 | NOS2 (0.49) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL30983358 | 0.81 | ARG1 (0.42) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL7363488 | 0.81 | ARG1 (0.42) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL12463782 | 0.79 | GSR (0.46) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL29891046 | 0.79 | GSR (0.46) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL2218978 | 0.79 | GSR (0.46) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL7285445 | 0.78 | MEN1 (0.56) | NOS2ARG1ARG2NOS1NOS3 | |
| SCHEMBL3444337 | 0.78 | BHMT (0.55) | NOS2NOS1NOS3BHMT | |
| SCHEMBL3444339 | 0.78 | BHMT (0.55) | NOS2NOS1NOS3BHMT | |
| SCHEMBL825904 | 0.78 | GSR (0.48) | NOS2ARG1ARG2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| EP-1694640-A4 | ANTI-CANCER AGENTS | UNIV QUEENSLAND (AU) | 2007-01-10 | — | — | EP | disclosed |
| EP-1694640-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005051901-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004290-A1 | Anti-Cancer Agents | TP53, TOP2A, MCL1 | NOS2 2019/4885ARG1 1669/4885ARG2 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.